Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis

[1]  P. Toth,et al.  Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. , 2019, Mayo Clinic proceedings.

[2]  J. Knowles,et al.  Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease , 2019, JAMA cardiology.

[3]  M. Farkouh,et al.  Adherence to Statin Therapy Among US Adults Between 2007 and 2014 , 2019, Journal of the American Heart Association.

[4]  R. Ofori-Asenso,et al.  Patterns of statin use and long‐term adherence and persistence among older adults with diabetes , 2018, Journal of diabetes.

[5]  P. Toth,et al.  High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk , 2018, Journal of the American Heart Association.

[6]  M. Banach,et al.  Management of Statin Intolerance in 2018: Still More Questions Than Answers , 2018, American Journal of Cardiovascular Drugs.

[7]  M. Banach,et al.  Optimizing Cholesterol Treatment in Patients With Muscle Complaints. , 2017, Journal of the American College of Cardiology.

[8]  David Madigan,et al.  Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making , 2017, Pharmacoepidemiology and drug safety.

[9]  Lisa M. LaVange,et al.  Multidimensional Evidence Generation and FDA Regulatory Decision Making: Defining and Using "Real-World" Data. , 2017, JAMA.

[10]  T. Brown,et al.  Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries , 2017, JAMA cardiology.

[11]  M. Pencina,et al.  Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis , 2017, Cardiovascular Drugs and Therapy.

[12]  P. Heidenreich,et al.  Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. , 2017, Circulation.

[13]  P. Heidenreich,et al.  Estimation of Eligibility for PCSK9 Inhibitors and Associated Costs Based on the FOURIER Trial: Insights from the Department of Veterans Affairs , 2017 .

[14]  M. Banach,et al.  Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. , 2017, Journal of the American College of Cardiology.

[15]  J. Kleijnen,et al.  A systematic review to assess adherence and persistence with statins , 2017, Current medical research and opinion.

[16]  M. Banach,et al.  Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. , 2016, International journal of cardiology.

[17]  R. Califf,et al.  Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.

[18]  B. Nordestgaard,et al.  Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. , 2016, European heart journal.

[19]  S. Celik,et al.  Understanding adherence to medications in type 2 diabetes care and clinical trials to overcome barriers: a narrative review , 2016, Current medical research and opinion.

[20]  M. Banach,et al.  Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel , 2015, Expert opinion on drug safety.

[21]  D. Lacaille,et al.  Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review , 2014, British journal of clinical pharmacology.

[22]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[23]  John Weinman,et al.  Intentional Non-Adherence to Medications by Older Adults , 2014, Drugs & Aging.

[24]  J. Ney,et al.  Association of Polypharmacy and Statin New-User Adherence in a Veterans Health Administration Population , 2013, The Annals of pharmacotherapy.

[25]  H. Daida,et al.  Mortality risk of triglyceride levels in patients with coronary artery disease , 2012, Heart.

[26]  Matthew K Ito,et al.  Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. , 2012, Journal of clinical lipidology.

[27]  M. Woodward,et al.  Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis , 2010, The Annals of pharmacotherapy.

[28]  M. Dorais,et al.  Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database. , 2010, The Canadian journal of cardiology.

[29]  J. Powles,et al.  Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins , 2010, Journal of Epidemiology & Community Health.

[30]  P Michael Ho,et al.  Medication Adherence: Its Importance in Cardiovascular Outcomes , 2009, Circulation.

[31]  G. Chodick,et al.  Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. , 2008, Clinical therapeutics.

[32]  N. Mayo,et al.  Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. , 2008, European heart journal.

[33]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[34]  Jun Ma,et al.  National Trends in Statin Use by Coronary Heart Disease Risk Category , 2005, PLoS medicine.

[35]  M. Banach,et al.  Statins: Then and Now. , 2019, Methodist DeBakey cardiovascular journal.

[36]  John B. Watkins,et al.  Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[37]  K. Birtcher.  When Compliance Is an Issue—How to Enhance Statin Adherence and Address Adverse Effects , 2014, Current Atherosclerosis Reports.

[38]  Janis P Bellack,et al.  Then and now. , 2011, The Journal of nursing education.

[39]  Lori S. Parsons.  Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques , 2001 .